Boehringer Ingelheim Venture Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 12
- Investments
- 69
- Portfolio
- 33
- Exits
- 12
Boehringer Ingelheim Venture Fund General Information
Description
Founded in 2010, Boehringer Ingelheim Venture Fund is the corporate venture capital arm of Boehringer Ingelheim headquartered in Ingelheim am Rhein, Germany. The firm seeks to invest in companies operating in the healthcare sectors.
Contact Information
Year Founded
2010
Investor Status
Actively Seeking New Investments
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Venture Capital
Primary Office
- Binger Strasse 173
- 55216 Ingelheim am Rhein
- Germany
+49 06132 000000
Boehringer Ingelheim Venture Fund Investments (69)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| T3 Pharma | 22-Jul-2020 | Later Stage VC | 000.00 | Drug Discovery | Generating Revenue | 00000 00000000000 00 |
| 0000000 0000000000 | 21-Jul-2020 | 0000 00000 | Drug Discovery | Startup | 000000000 00000 00.0 | |
| 0000000 | 16-Jun-2020 | 0000 00000 | 000 | Drug Discovery | Pre-Clinical Trials | 00000000 000000000 |
| 0000000 0000000000 | 16-Jun-2020 | 00000 00000 | 000.00 | Biotechnology | Clinical Trials - General | 00000 00000000000 00 |
| 000000 | 06-May-2020 | 00000 00000 | 000.00 | Enterprise Systems (Healthcare) | Generating Revenue | 000000 000 |
| 00000 000000000000 | 27-Apr-2020 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 00000 000 00.0 |
| 000000 | 02-Apr-2020 | 0000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000 000000000 00.0 |
| 00000000000 | 21-Jan-2020 | 00000 00000 | 000.00 | Drug Discovery | Pre-Clinical Trials | 00000000 000000000 |
| NBE Therapeutics | 10-Jan-2020 | Later Stage VC | 0000 | Drug Discovery | Generating Revenue | 000000 000000000 00.0 |
| Eyevensys | 08-Jan-2020 | Later Stage VC | 000.00 | Biotechnology | Generating Revenue | 00000 00000000000 00 |
Boehringer Ingelheim Venture Fund Exits (12)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| ArmaGen | 20-Apr-2020 | Merger/Acquisition | |
| 0000 000000000000 | 15-Jul-2019 | 000000000000000000 | 00000 |
| 00000 000000000000 | 01-Jun-2019 | 000000000000000000 | 00000 |
| 0000000 000000 | 18-Apr-2019 | 000 | 0000 |
| 000 000000000000 | 29-Mar-2019 | 000000000000000000 | |
| 0000000000000000 | 13-Sep-2018 | 000000000000000000 | 00000 |
| 0000-00 | 19-Apr-2018 | 000000000000000000 | 00000 |
| 00000000 | 26-Oct-2017 | 000000000000000000 | 00000 |
| 121 Bio | 01-May-2017 | Out of Business | |
| AMP Therapeutics | 03-Nov-2016 | Merger/Acquisition |
Boehringer Ingelheim Venture Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialBoehringer Ingelheim Venture Fund Team (21)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Frank Kalkbrenner MD | Director & Investment Manager | 00 | 0 | 0 | Ingelheim am Rhein, Germany |
| Ilka Wicke Ph.D | Director & Investment Manager | 00 | 0 | 0 | Ingelheim am Rhein, Germany |
| Martin Heidecker Ph.D | BIVF United States office | 0 | 0 | 0 | Cambridge, MA |
| Johannes Zanzinger | Executive | 0 | 0 | Ingelheim am Rhein, Germany | |
| Knut Elbers Ph.D | Senior Advisor Research Beyond Borders | 0 | 0 | Ingelheim am Rhein, Germany |
Boehringer Ingelheim Venture Fund Co-Investors (123)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| High-Tech Gründerfonds | 6 | 0 | 0 |
|
|
| Life Sciences Partners | 0 | 0 |
|
|
|
| BioMedPartners | 0 | 0 | 0 |
|
|
| Idinvest Partners | 0 | 0 | 0 |
|
|
| Kurma Partners | 0 | 0 | 0 |
|
|